Updates are available Correction dated 2023-03-14
Click to view Correction: https://doi.org/10.1007/s10238-023-01032-1
-
Authors
Poto, Remo https://orcid.org/0000-0002-4723-0167
laniro, Gianluca https://orcid.org/0000-0002-8318-0515
de Paulis, Amato https://orcid.org/0000-0003-0347-2540
Spadaro, Giuseppe https://orcid.org/0000-0001-7889-425X
Marone, Gianni https://orcid.org/0000-0002-9849-4701
Gasbarrini, Antonio https://orcid.org/0000-0003-4863-6924
Varricchi, Gilda https://orcid.org/0000-0002-9285-4657
-
Funding
Funding for this research was provided by:
Università degli Studi di Napoli Federico II
- License Information
-
More Information
Article History
Received: 29 December 2022
Accepted: 18 January 2023
First Online: 3 February 2023
Change Date: 14 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10238-023-01032-1
Declarations
:
: G.I. has received personal fees for acting as speaker for Biocodex, Danone, Sofar, Malesci, Metagenics, Tillotts Pharma, and for acting as consultant/advisor for Ferring Therapeutics, Giuliani, Metagenics, Tillotts Pharma. A.G. reports personal fees for consultancy for Eisai S.r.l., 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, Sinergie S.r.l. Board MRGE, and Sanofi S.p.A, personal fees for acting as a speaker for Takeda S.p.A, AbbVie, and Sandoz S.p.A, and personal fees for acting on advisory boards for VSL3 and Eisai. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
